Evolus (EOLS) Depreciation & Amortization (CF) (2017 - 2026)
Evolus (EOLS) posted Depreciation & Amortization (CF) of $2.3 million for Q1 2026, up 4.08% on a QoQ basis from $2.3 million in Q4 2025, and up 50.1% year-over-year from $1.6 million in Q1 2025.
Evolus (EOLS) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Evolus' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 50.1% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (up 52.06% YoY) and the FY2025 annual result came in at $7.5 million, up 41.7% from the prior year.
- Depreciation & Amortization (CF) was $2.3 million for Q1 2026 at Evolus, up from $2.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.3 million in Q1 2026 and bottomed at $853000.0 in Q2 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 54.65% — and 2025, when it jumped 79.48%.
- Evolus' Depreciation & Amortization (CF) stood at $1.0 million in 2022, then soared by 33.69% to $1.4 million in 2023, then gained by 0.07% to $1.4 million in 2024, then surged by 64.05% to $2.3 million in 2025, then grew by 4.08% to $2.3 million in 2026.
- Business Quant data shows EOLS's Depreciation & Amortization (CF) at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 2.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |